Oncoinvent Initiates Radspherin® Phase 2A Trial
![](https://mms.businesswire.com/media/20220824005602/en/1552636/4/oncoinvent_logo.jpg)
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, today announced that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin.